CryoPort (NASDAQ:CYRX) Posts Quarterly Earnings Results

CryoPort (NASDAQ:CYRX) released its quarterly earnings data on Thursday. The company reported ($0.25) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.18) by ($0.07), Zacks reports. CryoPort had a negative net margin of 20.05% and a negative return on equity of 7.20%. The business had revenue of $50.22 million during the quarter, compared to the consensus estimate of $48.66 million.

Here are the key takeaways from CryoPort’s conference call:

• Cryoport reported third-quarter revenue of $50.2 million, up 14% year over year, and raised its 2026 continuing-operations revenue outlook to $197 million–$199 million. Management characterized the outlook as prudent, with fourth-quarter growth expected to continue but potential upside.
• Life Sciences Services revenue rose 18%, including 20% growth in commercial cell and gene therapy activity; the company supports 23 commercial therapies and reported a record pipeline of 788 clinical trials, including 99 in Phase III. Management sees the pipeline and rising therapy adoption as drivers of future commercial growth.
• The company posted a second consecutive quarter of positive adjusted EBITDA, at $1.1 million and $1.8 million better year over year. Management expects further operating leverage as new BioServices capabilities come online, while noting that long-term margin targets remain goals rather than current results.
• Life science products revenue increased 8%, supported by animal-health demand and the Fusion freezer line, although management described animal health as cyclical and said China was stable but not a significant growth market. Four expected 2026 therapy application filings have shifted to 2027, while two potential fourth-quarter approvals have FDA decision dates.

CryoPort Stock Up 19.0%

CYRX traded up $3.05 during trading on Friday, hitting $19.10. The company’s stock had a trading volume of 2,585,565 shares, compared to its average volume of 854,852. The firm has a market cap of $967.42 million, a PE ratio of -19.69 and a beta of 1.89. CryoPort has a one year low of $7.61 and a one year high of $19.53. The business’s 50 day simple moving average is $16.98 and its 200-day simple moving average is $13.46.

Key Headlines Impacting CryoPort

Here are the key news stories impacting CryoPort this week:

• Positive Sentiment: Third-quarter revenue rose 14% year over year to $50.2 million, topping estimates of $48.66 million. Commercial cell and gene therapy revenue grew 20%; Cryoport supported a record 788 global clinical trials and 23 commercially approved therapies. Cryoport Reports Third Quarter 2026 Financial Results
• Positive Sentiment: The company raised its full-year 2026 revenue outlook to $197 million–$199 million, a key catalyst behind the favorable reaction to results. CryoPort Shares Rise After Q3 Revenue Beat, 2026 Guidance Raise
• Positive Sentiment: Analyst actions added support: Needham raised its price target to $28 from $19 and reiterated Buy, while KeyCorp lifted its target to $20 from $17 and maintained an Overweight rating. Needham Adjusts Price Target KeyCorp Rating
• Negative Sentiment: Adjusted earnings were a loss of $0.25 per share, missing consensus estimates of a $0.18–$0.19 loss and widening from a $0.18 loss a year earlier. The earnings shortfall may temper optimism around the revenue growth and raised outlook. CryoPort Reports Q3 Loss, Tops Revenue Estimates

Wall Street Analyst Weigh In

Several equities analysts have weighed in on CYRX shares. Guggenheim lifted their price objective on CryoPort from $16.00 to $19.00 and gave the company a “buy” rating in a report on Thursday, October 1st. Piper Sandler upgraded CryoPort to a “buy” rating in a research note on Tuesday, October 13th. Needham & Company LLC boosted their price objective on CryoPort from $19.00 to $28.00 and gave the company a “buy” rating in a research note on Friday. Roth Capital restated a “buy” rating and set a $21.00 price objective on shares of CryoPort in a research report on Friday, August 7th. Finally, KeyCorp lifted their target price on shares of CryoPort from $17.00 to $20.00 and gave the stock an “overweight” rating in a research note on Friday. Seven analysts have rated the stock with a Buy rating and two have given a Hold rating to the company. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $21.69.

Insider Buying and Selling at CryoPort

In related news, CEO Jerrell Shelton sold 28,800 shares of the firm’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $14.91, for a total transaction of $429,408.00. Following the completion of the transaction, the chief executive officer directly owned 1,201,814 shares of the company’s stock, valued at approximately $17,919,046.74. This trade represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 9.50% of the company’s stock.

About CryoPort

CryoPort, Inc (NASDAQ: CYRX) provides temperature-controlled supply chain solutions for the life sciences industry. The company supports the transportation, storage and management of biological materials, including cell and gene therapies, vaccines, biologics, reproductive materials and other temperature-sensitive products.

Its offerings include cryogenic and refrigerated shipping containers, biological material storage, transportation logistics, shipment monitoring and related supply chain management services.